Curanex Pharmaceuticals Inc Common Stock
Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients suffering from inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The company was formerly known as Fordman Pharma… Read more
Curanex Pharmaceuticals Inc Common Stock (CURX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.643x
Based on the latest financial reports, Curanex Pharmaceuticals Inc Common Stock (CURX) has a cash flow conversion efficiency ratio of -0.643x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.19 Million) by net assets ($14.29 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Curanex Pharmaceuticals Inc Common Stock - Cash Flow Conversion Efficiency Trend (2022–2024)
This chart illustrates how Curanex Pharmaceuticals Inc Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Curanex Pharmaceuticals Inc Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Curanex Pharmaceuticals Inc Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
US Copper Corp
OTCQB:USCUF
|
-0.542x |
|
CNL Capital EKES-AIFM
AT:CNLCAP
|
N/A |
|
COLLPLANT BIOTECH. IS-01
F:CPT
|
N/A |
|
Home Pottery Public Company Limited
BK:HPT
|
0.010x |
|
Mud & Hound Public Company Limited
BK:MUD
|
0.039x |
|
Quetzal Copper Corp.
V:Q
|
N/A |
|
Bright Green Corp
PINK:BGXXQ
|
-0.014x |
|
Armlogi Holding Corp. Common Stock
NASDAQ:BTOC
|
-0.086x |
Annual Cash Flow Conversion Efficiency for Curanex Pharmaceuticals Inc Common Stock (2022–2024)
The table below shows the annual cash flow conversion efficiency of Curanex Pharmaceuticals Inc Common Stock from 2022 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $503.36K | $-555.58K | -1.104x | -55169.43% |
| 2023-12-31 | $60.09K | $-120.00 | -0.002x | -100.61% |
| 2022-12-31 | $10.23K | $3.34K | 0.326x | -- |